Autologous Stem-Cell Transplantation in Patients With HIV-Related Lymphoma Export

@article{citeulike:5206064, abstract = {PurposePeripheral-blood autologous stem-cell transplantation (ASCT) in patients with HIV-related lymphoma (HIV-Ly) has been reported as a safe and useful procedure. Herein we report the European Group for Blood and Marrow Transplantation experience on patients with HIV-Ly undergoing ASCT. Patients and MethodsThis was a retrospective, multicentric, registry-based analysis. ResultsSince 1999, 68 patients from 20 institutions (median age, 41 years; range, 29 to 62 years) were included, diagnosed with non-Hodgkin's lymphoma (NHL; n = 50) or Hodgkin's lymphoma (n = 18). At the time of ASCT, 16 patients were in first complete remission (CR1); 44 patients were in CR more than 1, partial remission, or chemotherapy-sensitive relapse (chemo-S); and eight patients had chemotherapy-resistant disease. The median number of CD34+ cells infused was 4.5 x 106/kg (range, 1.6 to 21.2 x 106/kg). Median time to neutrophil and platelet engraftment were 11 days (range, 8 to 36 days) and 14 days (range, 6 to 455 days), respectively, with a cumulative incidence (CI) at 1 year of 95.6\% and 87\%, respectively. CI of nonrelapse mortality (NRM) was 7.5\% at 12 months after ASCT, mainly because of bacterial infections. CI of relapse was 30.4\% at 24 months, statistically related with not being in CR at ASCT (relative risk [RR] = 3.6), NHL histology other than diffuse large B-cell lymphoma (RR = 3.4), and use of more than two previous treatment lines (RR = 3). At a median follow-up of 32 months (range, 2 to 81 months), progression-free survival (PFS) was 56\%. Patients not in CR or with refractory disease at ASCT had poorer PFS (RR = 2.4 and 4.8, respectively). ConclusionSimilarly to HIV-negative patients with lymphoma, ASCT is a useful treatment for patients with HIV-Ly and is associated with low NRM, mainly when performed in early stages and chemo-S disease. 10.1200/JCO.2008.18.2683}, author = {Balsalobre, Pascual and Diez-Martin, Jose L. and Re, Alessandro and Michieli, Mariagrazia and Ribera, Jose M. and Canals, Carmen and Rosselet, Anne and Conde, Eulogio and Varela, Rosario and Cwynarski, Kate and Gabriel, Ian and Genet, Philippe and Guillerm, Gaelle and Allione, Bernardino and Ferrant, Augustin and Biron, Pierre and Espigado, Ildefonso and Serrano, David and Sureda, Anna}, citeulike-article-id = {5206064}, citeulike-linkout-0 = {http://dx.doi.org/10.1200/JCO.2008.18.2683}, citeulike-linkout-1 = {http://jco.ascopubs.org/cgi/content/abstract/27/13/2192}, citeulike-linkout-2 = {http://view.ncbi.nlm.nih.gov/pubmed/19332732}, citeulike-linkout-3 = {http://www.hubmed.org/display.cgi?uids=19332732}, day = {1}, doi = {10.1200/JCO.2008.18.2683}, journal = {J Clin Oncol}, keywords = {immunodeficiency, lymphoma, transplant}, month = {May}, number = {13}, pages = {2192--2198}, posted-at = {2009-07-20 03:30:15}, priority = {2}, title = {Autologous Stem-Cell Transplantation in Patients With HIV-Related Lymphoma}, url = {http://dx.doi.org/10.1200/JCO.2008.18.2683}, volume = {27}, year = {2009} }

TY - JOUR ID - citeulike:5206064 L3 - citeulike-article-id:5206064 N2 - PurposePeripheral-blood autologous stem-cell transplantation (ASCT) in patients with HIV-related lymphoma (HIV-Ly) has been reported as a safe and useful procedure. Herein we report the European Group for Blood and Marrow Transplantation experience on patients with HIV-Ly undergoing ASCT. Patients and MethodsThis was a retrospective, multicentric, registry-based analysis. ResultsSince 1999, 68 patients from 20 institutions (median age, 41 years; range, 29 to 62 years) were included, diagnosed with non-Hodgkin's lymphoma (NHL; n = 50) or Hodgkin's lymphoma (n = 18). At the time of ASCT, 16 patients were in first complete remission (CR1); 44 patients were in CR more than 1, partial remission, or chemotherapy-sensitive relapse (chemo-S); and eight patients had chemotherapy-resistant disease. The median number of CD34+ cells infused was 4.5 x 106/kg (range, 1.6 to 21.2 x 106/kg). Median time to neutrophil and platelet engraftment were 11 days (range, 8 to 36 days) and 14 days (range, 6 to 455 days), respectively, with a cumulative incidence (CI) at 1 year of 95.6% and 87%, respectively. CI of nonrelapse mortality (NRM) was 7.5% at 12 months after ASCT, mainly because of bacterial infections. CI of relapse was 30.4% at 24 months, statistically related with not being in CR at ASCT (relative risk [RR] = 3.6), NHL histology other than diffuse large B-cell lymphoma (RR = 3.4), and use of more than two previous treatment lines (RR = 3). At a median follow-up of 32 months (range, 2 to 81 months), progression-free survival (PFS) was 56%. Patients not in CR or with refractory disease at ASCT had poorer PFS (RR = 2.4 and 4.8, respectively). ConclusionSimilarly to HIV-negative patients with lymphoma, ASCT is a useful treatment for patients with HIV-Ly and is associated with low NRM, mainly when performed in early stages and chemo-S disease. 10.1200/JCO.2008.18.2683 IS - 13 JF - J Clin Oncol EP - 2198 TI - Autologous Stem-Cell Transplantation in Patients With HIV-Related Lymphoma VL - 27 SP - 2192 KW - immunodeficiency KW - lymphoma KW - transplant AU - Balsalobre, Pascual AU - Diez-Martin, Jose AU - Re, Alessandro AU - Michieli, Mariagrazia AU - Ribera, Jose AU - Canals, Carmen AU - Rosselet, Anne AU - Conde, Eulogio AU - Varela, Rosario AU - Cwynarski, Kate AU - Gabriel, Ian AU - Genet, Philippe AU - Guillerm, Gaelle AU - Allione, Bernardino AU - Ferrant, Augustin AU - Biron, Pierre AU - Espigado, Ildefonso AU - Serrano, David AU - Sureda, Anna PY - 2009/05/01/ UR - http://dx.doi.org/10.1200/JCO.2008.18.2683 ER -